<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB"><gtr:id>AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB</gtr:id><gtr:name>Oxford University Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Churchill Site</gtr:line1><gtr:line2>Old Road</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX3 7LJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Psychiatry</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB"><gtr:id>AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB</gtr:id><gtr:name>Oxford University Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Churchill Site</gtr:line1><gtr:line2>Old Road</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX3 7LJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/19D1396C-ECFC-4111-9838-02133E0C97EF"><gtr:id>19D1396C-ECFC-4111-9838-02133E0C97EF</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Harrison</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DB2926BA-C983-407D-8CF8-78F05AD3854A"><gtr:id>DB2926BA-C983-407D-8CF8-78F05AD3854A</gtr:id><gtr:firstName>Angela</gtr:firstName><gtr:surname>Vincent</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/612700E1-113C-4552-85EA-A396E5289965"><gtr:id>612700E1-113C-4552-85EA-A396E5289965</gtr:id><gtr:firstName>Belinda</gtr:firstName><gtr:otherNames>Rosalind</gtr:otherNames><gtr:surname>Lennox</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F2D0395A-5A42-41E4-9E08-E4D92C0E19CD"><gtr:id>F2D0395A-5A42-41E4-9E08-E4D92C0E19CD</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>Brian</gtr:otherNames><gtr:surname>Jones</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ012939%2F1"><gtr:id>E72282CB-4DC6-4511-8458-8004C00EE270</gtr:id><gtr:title>Identifying the prevalence of antibodies to neuronal membrane targets in first episode psychosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J012939/1</gtr:grantReference><gtr:abstractText>In the last ten years there have been breakthroughs in the discovery of new treatment responsive causes of limbic encephalitis. This is a rare, life threatening brain disorder. These new causes have been antibodies against targets on the surface of brain cells. In the descriptions of these new disorders patients often present with promninent psychiatric symptoms, with symptoms of psychosis such as hallucinations and delusions and disordered thinking and impaired memory. However they also develop difficulties with fits, loss of unconsciousness, blood pressure control or electrolyte disturbance which means that they end up under the management of neurologists or intensive care specialists rather than psychiatrists. We were interested whether a proportion of patients with purely psychiatric symptoms of the disorder would also have these antibodies. We therefore tested 47 patients with a first episode of psychosis, without other features of limbic encephalitis and found that 3 of them did have these antibodies. We have since identified, without systematic screening a further 9 patients, and have treated 4 of these by treating their immune system rather than traditional psychiatric medication. This gives further support to the theory that the antibodies are causing the psychosis in these patients. We now wish to establish just how common this disorder is. We want to screen a larger number of patients for all known antibodies that can cause limbic encephalitis. This will help us to estimate how significant a disorder this is, and help with planning clinical services.</gtr:abstractText><gtr:technicalSummary>anti-NMDAR and anti-VGKC complex antibodies have been identified as treatment responsive causes of limbic encephalitis. In both disorders psychotic symptoms are the predominant presenting symptoms. There are strong theoretical reasons to associate both of these antibodies with psychotic illness. We have identifed cases of primary psychotic illness, without the other features typical of disorders, with both of these antibodies. We have identified some cases prospectively and have successfully treated 4 cases solely with immunotherapy. These preliminary findings suggest that these antibodies are pathogenic in some cases of first episode psychosis. We therefore wish to establish the prevalence of these antibodies in a cohort of patients at first presentation psychosis. This is a pilot study to establish the prevalence of the disorder. If the number of cases warrants further investigation we would then wish to undertake a larger project to fully characterise the phenotype of this disorder and guide treatment planning in first episode psychosis</gtr:technicalSummary><gtr:potentialImpactText>Health:
In other cases of limbic encephalitis caused by these antibodies patients respond to immunotherapy, especially if treatment is started early and aggressively (Irani et al 2010). A significant proportion of cases are paraneoplastic, most commonly associated with ovarian/testicular teratoma. In these cases early removal of the teratoma is also associated with an excellent outcome. In the cases of primary psychosis with antibodies that we have treated with immunotherapy in each case the patient was an inpatient on a psychiatric ward when identified, responded to steroids and/or plasma exchange and was able to be discharged from hospital afterwards. There is therefore the potential for significant benefit for the individual patients, with an identifiable, treatable cause for their psychotic illness.

Wealth:
Psychotic illnesses accounts for a huge cost to the economy, both through direct and indirect costs. Psychosis accounts for more than 50% of all psychiatric inpatient beds. The peak age of onset is in adolescence and at the moment is considered a lifelong disorder. Current treatments are helpful for some symptoms of the disorder, but do not change the illness course. If an aetiology can be identified in even a small proportion of patients there will be significant gains to the economy.

Psychiatric services
The researchers in the application work in academic health science centres with considerable infrastructure to support the rapid translation of new evidence into practice (NIHR BRCs and CLAHRC). The service implications of this research may be the reconfiguration of mental health services to allow access to appropriate investigations and treatments for this new disorder.

Commercial
If novel antigens of relevance to psychosis are discovered, Euroimmun AG would be in a position to develop multiple antigen testing kits specifically for psychiatric disorders, in collaboration with the applicants.</gtr:potentialImpactText><gtr:fund><gtr:end>2014-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>71513</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxford University Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>joint neuroimmunology-psychiatry clinic established</gtr:description><gtr:id>C3217726-83F3-4B56-9594-82DEC726EE2F</gtr:id><gtr:impact>Research nurse - Jon Revis, Neurologist Camilla Buckley, myself as psychiatrist. Has led to application for further funding applications to study the patient cohort</gtr:impact><gtr:outcomeId>545276cbb636e3.67944367-1</gtr:outcomeId><gtr:partnerContribution>contribution to the joint clinic</gtr:partnerContribution><gtr:piContribution>We have established a joint clinic which I run with Camilla Buckley, consultant neurologist at OUH for all patients that we have identified with antineuronal cell surface antibodies</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>multiple media appearances TV and radio, to coincide with publication of paper</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>592623F8-02EB-47C5-9D39-D00F3769B901</gtr:id><gtr:impact>multiple media appearances on 8th December 2016, including: The Today programme Radio 4 at 06:33, 07:22, Victoria Derbyshire show BBC2 09.30, BBC World service hourly television, and radio news, One O'Clock news, Six O'Clock news. Also in print in: Daily Mail, The Telegraph, The Metro, Mail on Sunday</gtr:impact><gtr:outcomeId>58af4a076ad509.45555553</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at The 7th Oxford Neurology Course</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>21D4C49D-B3E3-4B4B-A077-10272E7F6124</gtr:id><gtr:impact>Presentation entitled: &amp;quot;The neuropsychiatric manifestations of NMDAR antibodies&amp;quot; a the 7th Oxford Neurology Course, St Anne's College, Oxford 29th June 2016</gtr:impact><gtr:outcomeId>58a457af2004d6.79216559</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>https://www.ndcn.ox.ac.uk/events/7th-oxford-neurology-course-programme.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation: The psychiatric management of autoimmune encephalitis at RCPsych International Congress 2015, Birmingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4E7389FB-7B88-4811-BA37-E77CC7308E6F</gtr:id><gtr:impact>Plenary: Organic and Neuropsychiatry
TC2 Disorders at the interface of neurology and psychiatry - Part 2 New disorders
The psychiatric management of autoimmune encephalitis</gtr:impact><gtr:outcomeId>56c4a63107eec7.18471118</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.rcpsych.ac.uk/traininpsychiatry/conferencestraining/internationalcongress2015/programme/tuesday30june2015.aspx</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Schizophrenia International Research Society presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>99222DEE-C214-4E45-BDE1-B196BF1A8719</gtr:id><gtr:impact>300 psychiatry researchers from across the world attended a symposium on autoimmune psychosis at the international sociaty meeting

collaborations made with other researchers in the field</gtr:impact><gtr:outcomeId>54527a2ca95714.20680092</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>medical student teaching</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>FB18F398-5A5A-4BEE-8853-5E95BBA8C948</gtr:id><gtr:impact>I run a new science session for medical students as part of their psychiatry rotation where I share the story of the research and stimulate their thinking around the neurobiological basis of psychiatric illness and the challenges of finding a brain abnormality that requires a different approach to treatment

Interest in placements and special study modules working with me</gtr:impact><gtr:outcomeId>545273632a7338.62296724</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal College of Psychiatrists conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>144FEDD9-9E55-4E55-B8F9-8954C762D8EF</gtr:id><gtr:impact>300 attended talk at Royal college Psychiatrists conference. I presented clinical implications of my research which sparked a lot of interest and discussion about change in practice required, and contact made with clinicians from across UK as well as France and Ireland

A further 2 sites were added to the PPiP research study</gtr:impact><gtr:outcomeId>54511e7355eb63.33091248</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.rcpsych.ac.uk/traininpsychiatry/conferencestraining/facultysectionconferences/generaladultpsychiatry2014.aspx</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Autoantibodies encephalitis</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F9CEE8E5-9A89-4186-9A01-BCDA472390B6</gtr:id><gtr:impact>Royal College of Psychiatrists Faculty of Liaison Psychiatry Annual Residential Conference 'Integrated Psychological Medicine' 
11 May 2016 Holiday Inn City Centre, Birmingham - Talk on Autoantibodies encephalitis</gtr:impact><gtr:outcomeId>58a335de7d7633.07630229</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.rcpsych.ac.uk/pdf/CALC_Liaison%20Faculty%202016prog3March.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Epilepsy masterclass</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B4F7F8E0-A55A-4B8C-9EC5-8F60775D27C4</gtr:id><gtr:impact>200 participants at a one day masterclass where I spoke on psychiatric aspects of channelopathies

Increased interest and collaboration from researchers and clinicians</gtr:impact><gtr:outcomeId>545275b1a2ca67.08245144</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Daily Mail feature article</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>08D7694E-FA88-4F87-9024-4097E8A2CFE1</gtr:id><gtr:impact>Published in paper and online edition of Daily Mail

Multiple contacts from patients and carers interested in the research</gtr:impact><gtr:outcomeId>stEHzGQzLQJ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.dailymail.co.uk/health/article-2316825/Driven-insane-immune-One-womans-terrifying-story-reveals-rogue-particles-brain-trigger-mental-illness.html</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford Neuroscience symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3E012C01-A023-4A13-AF5C-70DB118C4770</gtr:id><gtr:impact>presnted my research to the Oxford Neuroscience community and invited visitors

Was approached by head of neuroscience at Wellcome Trust to apply for funding</gtr:impact><gtr:outcomeId>54527aa9e6fc59.54089023</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Department of Psychiatry autumn school</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>64480B3D-A6AD-4C8D-8C21-AE59EA3472DF</gtr:id><gtr:impact>Ran a workshop at the University of Oxford Department of Psychiatry autumn summer school for 30 medical students and Foundation year doctors on a career in academic psychiatry.

3 medical students are working with me on placements and for extra experience in the clinic and the lab.</gtr:impact><gtr:outcomeId>5452726bc55874.26003408</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation: The prevalence of antibodies to neuronal membrane targets in first episode psychosis, RCPsych International Congress 2015, Birmingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FB00E1B8-83E5-4EB9-A3CD-5C4862EB5E4A</gtr:id><gtr:impact>Plenary: Psychosis and mood disorders
S43 Immune Pathogenesis of Psychosis
The prevalence of antibodies to neuronal membrane targets in first episode psychosis</gtr:impact><gtr:outcomeId>56c4a77c9cfee7.53350108</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.rcpsych.ac.uk/traininpsychiatry/conferencestraining/internationalcongress2015/programme/thursday2july2015.aspx</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at RCP Advanced Medicine Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>23FBD33F-6201-4C80-A32F-4A9E1F9B936A</gtr:id><gtr:impact>Presentation entitled &amp;quot;Autoimmune encephalopathies - latest advances&amp;quot; at Royal College of Physcians Advanced Medicine Conference in Birmingham, 20 June, 2016</gtr:impact><gtr:outcomeId>58a4522c027130.02755436</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.rcplondon.ac.uk/events/advanced-medicine-manchester</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at the 6th European Conference on Schizophrenia Research (ECSR)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>15B82998-F0C2-4FCB-9CE8-A07BCBBF682D</gtr:id><gtr:impact>Symposium presentation entitled: &amp;quot;The diagnosis and management of autoimmune encephalitis in psychiatric settings&amp;quot; at the 6th European Conference on Schizophrenia Research (ECSR), 24/11/2016</gtr:impact><gtr:outcomeId>58a464ba54f801.46642512</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.cpo-media.net/DGPPN/2016/Programm/HTML/files/assets/common/downloads/publication.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Interview for The Naked Scientists (www.thenakedscientists.com), University of Cambridge, 24 March 2015</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>350CD780-8FAF-4DD5-BDCD-3E29A86E2EBA</gtr:id><gtr:impact>Recorded interview/discussion entitled &amp;quot;Immune attack on the brain&amp;quot;.</gtr:impact><gtr:outcomeId>56d44dfe927ff1.13155767</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.thenakedscientists.com/HTML/interviews/interview/1001216/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Grand round presentations and clinical research network meetings</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>0DDA045E-E344-4FB5-9B0D-C1A92ABDCB34</gtr:id><gtr:impact>I have presented at grand rounds at: Royal London Hospital, Oxford University Hospitals Trust, Cambridge University Hospitals NHS FT, Berkshire Healthcare NHS FT, MHRN national conference Liverpool 2014

Increase in recruitment to study, increase in clinical referrals</gtr:impact><gtr:outcomeId>5452750e450a18.93093521</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio 4 broadcast an exploration into this new understanding of psychiatric disorders earlier this year: The Inflamed Mind</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2A930CEF-AAD5-4B15-91AD-515F2B140469</gtr:id><gtr:impact>BBC Radio 4 broadcast an exploration into this new understanding of psychiatric disorders earlier this year: The Inflamed Mind.</gtr:impact><gtr:outcomeId>58a46a9bcb7773.96008194</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/programmes/b07pj2pw</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>092E31FF-F694-48D0-84FA-0C206D96BF71</gtr:id><gtr:impact>BBC podcast on Naked Scientist website.

Linked on University of Oxford website. Contact from several patients asking questions about the research</gtr:impact><gtr:outcomeId>qTznPji24KX</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.thenakedscientists.com/HTML/content/interviews/interview/1000334/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clinical Phenotype of Patients With NMDAR Antibodies</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>915C00E0-5B02-48D9-ABC6-2DEAD0BB0636</gtr:id><gtr:impact>Clinical Phenotype of Patients With NMDAR Antibodies - a presentation at the 5th Schizophrenia International 
Research Society Conference on 4th April 2016</gtr:impact><gtr:outcomeId>58a3328dea2b88.01339415</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.schizophreniaconference.org/wp-content/uploads/2016/04/SIRSProgramBook2016.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2711780</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DPFS</gtr:description><gtr:end>2020-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N019067/1</gtr:fundingRef><gtr:id>B03B5A60-D62E-4895-8E26-F2EF35B1095A</gtr:id><gtr:outcomeId>56d451b0402787.53337426</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100070</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Confidence in Concept Scheme</gtr:department><gtr:description>MRC Confidence in Concept award University of Oxford</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>90E92D4D-D7AE-4669-815A-BBB1FF94F31C</gtr:id><gtr:outcomeId>54511b97271d21.19345339</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>284176</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Stanley Medical Research Institute treatment trials</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Stanley Medical Research Institute (SMRI)</gtr:fundingOrg><gtr:id>7A52187F-514C-4DAC-8A30-A3B337F71F3E</gtr:id><gtr:outcomeId>56d450c7a163c8.69160101</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>change to treatment algorithm for psychosis and schizophrenia</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>1B1B3465-482B-4917-8636-54E6025D87C2</gtr:id><gtr:outcomeId>54511cebebf769.70006795</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7C313D93-DB16-4390-9921-80522E12830A</gtr:id><gtr:title>N-Methyl-D-Aspartate Receptor Autoantibodies in Psychiatric Illness.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c07a2cd5141499e3dde9061d97e21333"><gtr:id>c07a2cd5141499e3dde9061d97e21333</gtr:id><gtr:otherNames>Zandi MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>56c4973fc5ca69.25909977</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F67C07A-313B-4E6C-930B-E0C43CC10CB1</gtr:id><gtr:title>Treating Sleep Problems in Young People at Ultra-High Risk of Psychosis: A Feasibility Case Series.</gtr:title><gtr:parentPublicationTitle>Behavioural and cognitive psychotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5592abb0acfc0604d67da2a0c7fb585"><gtr:id>e5592abb0acfc0604d67da2a0c7fb585</gtr:id><gtr:otherNames>Bradley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1352-4658</gtr:issn><gtr:outcomeId>5a69ea77c5a6c6.72906096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C203D37A-10CF-45B3-B1F9-44AD75CCCABC</gtr:id><gtr:title>Bullying victimisation and psychosis: The interdependence and independence of risk trajectories</gtr:title><gtr:parentPublicationTitle>BJPsych Advances</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b70a371258994cbc85c8abec358bfa73"><gtr:id>b70a371258994cbc85c8abec358bfa73</gtr:id><gtr:otherNames>Catone G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a69ea773ab855.65497980</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>264E5194-7704-4BBC-AA56-DE30DCDE51C1</gtr:id><gtr:title>Synaptic and Neuronal Autoantibody-Associated Psychiatric Syndromes: Controversies and Hypotheses.</gtr:title><gtr:parentPublicationTitle>Frontiers in psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9d06d07b22b4e47a32b6812ae82e4f7"><gtr:id>e9d06d07b22b4e47a32b6812ae82e4f7</gtr:id><gtr:otherNames>Al-Diwani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-0640</gtr:issn><gtr:outcomeId>5a69ea779954d2.89274498</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23416F44-EA74-4860-A795-CDC7280EDD47</gtr:id><gtr:title>Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c07a2cd5141499e3dde9061d97e21333"><gtr:id>c07a2cd5141499e3dde9061d97e21333</gtr:id><gtr:otherNames>Zandi MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5452706651dc69.48686518</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34CADB21-A20B-4C71-8403-08BF3D44925D</gtr:id><gtr:title>Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study</gtr:title><gtr:parentPublicationTitle>The Lancet Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8188329c3463c9c0e4b042a8f5417b98"><gtr:id>8188329c3463c9c0e4b042a8f5417b98</gtr:id><gtr:otherNames>Lennox B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>589dee9fdaa778.67937282</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16672F42-F27C-4075-9543-66CD7589D6CB</gtr:id><gtr:title>NMDAR antibodies in first episode psychosis: conclusions too inflammatory given results? - Authors' reply</gtr:title><gtr:parentPublicationTitle>The Lancet Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52329ae785e789fb6117f1ddca3cd12b"><gtr:id>52329ae785e789fb6117f1ddca3cd12b</gtr:id><gtr:otherNames>Lee M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a6f2ffe1f08a0.91975971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>133DF5F4-DF7E-4DD7-B844-86877D72C0D9</gtr:id><gtr:title>Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment.</gtr:title><gtr:parentPublicationTitle>The lancet. Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/837a4061ace27116836453898febcf5c"><gtr:id>837a4061ace27116836453898febcf5c</gtr:id><gtr:otherNames>Khandaker GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2215-0366</gtr:issn><gtr:outcomeId>56c4973fee7f25.88055877</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE4C90C0-1418-4288-8347-95E5D094792C</gtr:id><gtr:title>Autoimmune encephalitis: a potentially treatable cause of mental disorder</gtr:title><gtr:parentPublicationTitle>Advances in Psychiatric Treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/120e844e1d3ceda1bf9837bb5458c0be"><gtr:id>120e844e1d3ceda1bf9837bb5458c0be</gtr:id><gtr:otherNames>Rickards H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>545119a0b45e84.83488914</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CCC41FA-2229-4D16-B233-B897B40CD810</gtr:id><gtr:title>Antibodies to the N-methyl-D-aspartate receptor and other synaptic proteins in psychosis.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/973720135ae2c77f231bf59c3e4bb01b"><gtr:id>973720135ae2c77f231bf59c3e4bb01b</gtr:id><gtr:otherNames>Deakin J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>pm_22895_25_23988024</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J012939/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>